Respiratory syncytial virus bronchiolitis: Prevention and treatment

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 14, 2008, Pages 2451-2458

  Faber, Tina E ^a   Kimpen, Jan L L ^b   Bont, Louis J ^b  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bronchiolitis; Prevention; Respiratory syncytial virus; Review; Treatment

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CLARITHROMYCIN; CORTICOSTEROID; DEXAMETHASONE; DNA VACCINE; GLUCOCORTICOID; HELIOX; IMMUNOGLOBULIN; INACTIVATED VACCINE; IPRATROPIUM BROMIDE; LIVE VACCINE; MACROLIDE; MEASLES MUMPS RUBELLA VACCINE; PALIVIZUMAB; PLACEBO; PREDNISOLONE; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; SALBUTAMOL; SHORT ACTING DRUG; VIRUS VACCINE;

AEROSOL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; CENTRAL SEROUS RETINOPATHY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CUSHING SYNDROME; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG PREFERENCE; DRUG SAFETY; HEMOLYTIC ANEMIA; HUMAN; HYPERNATREMIA; HYPERTENSION; HYPOKALEMIA; INFECTION PREVENTION; LONG TERM CARE; LUNG INFECTION; MIXED INFECTION; NEBULIZATION; NONHUMAN; OCCUPATIONAL EXPOSURE; PASSIVE IMMUNIZATION; PRENATAL DRUG EXPOSURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TERATOGENICITY; VACCINATION; VIRAL BRONCHIOLITIS; VIRUS INFECTION; WHEEZING;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BRONCHIOLITIS, VIRAL; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULINS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIRAL VACCINES;

EID: 54349116513     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.14.2451     Document Type: Review

References (80)

1. Bloemers BL, Van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 2007;120(4):e1076-81
2. Semple MG, Cowell A, Dove W, et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis 2005;191(3):382-6
3. Tulic MK, Hurrelbrink RJ, Prele CM, et al. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J Immunol 2007;179(1):132-40
4. Amanatidou V, Sourvinos G, Apostolakis S, et al. RANTES promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis. Pediatr Infect Dis J 2008;27(1):38-42
5. Nwankwo MU, Okuonghae HO, Currier G, Schuit KE. Respiratory syncytial virus infections in malnourished children. Ann Trop Paediatr 1994;14(2):125-30
6. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003;143(5 Suppl):S118-26
7. Shann F, Steinhoff MC. Vaccines for children in rich and poor countries. Lancet 1999;354(Suppl 2):SII7-11
8. Williams BG, Gouws E, Boschini-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2(1):25-32
9. Hashem M, Hall CB. Respiratory syncytial virus in healthy adults; the cost of a cold. J Clin Virol 2003;27(1):14-21
10. Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illnesses: an observational study. Lancet 2001;358(9291):1410-6
11. O'Shea MK, Ryan MA, Hawksworth AW, et al. Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment. Clin Infect Dis 2005;41(3):311-7
12. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352(17):1749-59
13. Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert Rev Vaccines 2008;7(2):249-58
14. Barry W, Cockburn F, Cornwall R, et al. Ribavirin aerosol fur acute bronchiolitis. Arch Dis Child 1986;61:593-7
15. Groothuis JR, Woodin KA, Katz R, et al. Early ribavirin treatment of respiratory syncytial virus infection in high-risk children. J Pediatr 1990;117:792-8
16. Hall CB, McBride JT, Gala CL, et al. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985;254:3047-51
17. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection: a randomized double-blind study. N Engl J Med 1983;308:1443-7
18. Janai HK, Stutman HR, Zaleska M, et al. Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J 1993;12:214-8
19. Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983;72:613-8
20. Jefferson LS, Coss-Bu JA, Englund JA, et al. Respiratory system mechanics in patients receiving aerosolized ribavirin during mechanical ventilation for suspected respiratory syncytial viral infection. Pediatr Pulmonol 1999;28(2):117-24
21. Guerguerian AM, Gauthier M, Lebel MH, et al. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. Am J Respirat Crit Care Med 1999;160(3):829-34
22. Law BJ, Wang EEL, Stephens D. Ribavirin does not reduce hospital stay in patients with respiratory syncytial virus lower respiratory tract infection. Pediatr Res 1995;37:110A
23. Moler FW, Steinhart CM, Ohmit SE, Stidham GL. Effectiveness of ribavirin in otherwise well infants with respiratory syncytia] virus-associated respiratory failure. J Pediatr 1996;128:422-8
24. Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2004;4:CD000181
25. American Academy of Pediatrics, Committee on Infectious Diseases. Reassessment of indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996;97:137-40
26. Boeckh M, Englund J, Yufeng L, et al.; for the NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007;44:245-9
27. Chavez-Bueno S, Mejias A, Merryman RA, et al. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007;26(12):1089-93
28. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008;46(3):402-12
29. Stein RT, Sherill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13. Lancet 1999;354:541-5
30. Perez-Yarza EG, Moreno A, Lazaro P, et al. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J 2007;26(8):733-9
31. Hammer J, Numa A, Newth C. Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. J Pediatr 1995;127:485-87
32. Flores G, Horwitz RI. Efficacy of beta-2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics 1997;100:233-9
33. Gadomski AM, Bhasale AL. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2006;3:CD001266
34. Van Woensel J, Kimpen J. Therapy for respiratory tract infections caused by respiratory syncytial virus. Eur J Pediatr 2000;159(6):391-8
35. Wainwright C, Altamirano L, Cheney J, et al. A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. N Engl J Med 2003;349(1):27-35
36. Langley JM, Smith MB, Leblanc JC, et al. Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial. BMC Pediatr 2005;5(1):7
37. Cambonie G, Milesi C, Fournier-Favre S, et al. Clinical effects of heliox administration for acute bronchiolitis in young infants. Chest 2006;129:676-82
38. Cannon MJ, Openshaw PJM, Akonas BA. Lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988;168:1163-8
39. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991;88:1026-33
40. Peebles RS, Graham BS. Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2005;28(5):616-21
41. Buckingham SC, Bush AJ, Devincenzo JP. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J 2000;19:113-7
42. Openshaw PJ. Antiviral immune responses and lung inflammation after respiratory syncytial virus infection. Proc Am Thorac Soc 2005;2(2):121-5
43. Karron BA, Singleton RJ, Bulkow L, et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J Infect Dis 1999;180:41-9
44. Tripp RA, Oshansky C, Alvarez R. Cytokines and respiratory syncytial virus infection. Proc Am Thorac Soc 2005;2(2):147-9
45. Garrison MM, Christakis DA, Harvey E, et al. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics 2000;105:E441-6
46. Patel H, Platt R, Lozano JM, Wang EE. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2004;3:CD004878
47. Blom D, Ermers M, Bont L, et al. Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitis wheezing. Cochrane Database Syst Rev 2007;1:CD004881
48. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr 1998;157:215-20
49. Brand PLP, Vaessen-Verberne AAPH. Differences in management of bronchiolitis between hospitals in The Netherlands. Dutch Paediatric Respiratory Society. Eur J Pediatr 2000;159:343-7
50. Vogel AM, Lennon DR, Harding JE, et al. Variations in bronchiolitis management between five New Zealand hospitals: can we do better? J Paediatr Child Health 2003;39:40-5
51. Ichiyama T, Nishikawa M, Yoshitomi T, et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001;45:44-7
52. Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomized, placebo-controlled trial. Eur Respirat J 2007;29:91-7
53. Kneyber MCJ, Blusse Van Oud-Albas H, Van Vliet M, et al. Concurrent bacterial infection and prolonged mechanical ventilation in infants with respiratory syncytial virus lower respiratory tract infection. Intensive Care Med 2005;131:680-5
54. Thornburn K, Harigopal S, Reddy V, et al. High incidence of pulmonary bacterial co-infection in children ventilated for severe respiratory syncytial virus (RSV) bronchiolitis. Thorax 2006;61:611-5
55. Duttweiler L, Nadal D, Frey B. Pulmonary and systemic bacterial co-infections in severe RSV bronchiolitis. Arch Dis Child 2004;89:1155-7
56. Randolph AG, Reder L, Englund JA. Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit. Pediatr Infect Dis J 2004;23:990-4
57. Bloomfield P, Dalton D, Karleka A, et al. Bacteraemia and antibiotic use in respiratory syncytial virus infections. Arch Dis Child 2004;89:363-7
58. Korppi M. Macrolides and bronchiolitis in infants. Eur Respir J 2007;29(6):1283
59. Kneyber MCJ, Kimpen JLL. Antibiotics in RSV bronchiolitis: still no evidence of effect. Eur Respirat J 2007;29(6):1285
60. Kneyber MC, Van Woensel JB, Uijtendaal E, et al.; on Behalf of the Dutch Antibiotics in RSV Trial Research Group. Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial. Pediatr Pulmonol 2008;43(2):142-9
61. Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89(4):405-21
62. Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006;12(8):905-7
63. Collins PL, Murphy BR. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2005;2(2):166-73
64. Kneyber MC, Kimpen JL. Current concepts on active immunization against respiratory syncytial virus for infants and young children. Pediatr Infect Dis J 2002;21(7):685-96
65. Piedra PA. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 2003;22(2 Suppl):S94-9
66. Polack FP, Karron RA. The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 2004;23(1 Suppl):S65-73
67. Venkatesh MP, Weisman LE. Prevention and treatment of respiratory syncytial virus infection in infants: an update. Expert Rev Vaccines 2006;5(2):261-8
68. Van Drunen Littel-Van Den Hurk S, Mapletoft JW, Arsie N, Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007;17(1):5-34
69. Meissner HC, Fulton DR, Groothuis JR, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993;37:1655-8
70. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30
71. American Academy Of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics 1997;99:645-50
72. Fuller H, Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev 2006;18(4):CD004883
73. The IMPACT-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-7
74. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-40
75. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442-6
76. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-27
77. Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: a 'real life' experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 2006;41:1167-74
78. Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab long-term respiratory outcomes study group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007;151:34-42
79. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008;317:103-23
80. Mejias A, Chavez-Buena S, Raynor MB, et al. Motavizumab, a neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by RSV in the mouse model. Virol J 2007;4:109